# STK25 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- STK25 is a serine/threonine kinase belonging to the GCKIII subfamily, crucial for integrating stress responses, metabolic control, cell polarity, and survival pathways. Its dysregulation is implicated in metabolic diseases like NAFLD and type 2 diabetes, cardiovascular pathology, neurodevelopmental disorders, and various cancers.
- The *STK25* gene, located at 2q37.3, is regulated by a CpG island promoter with binding sites for SP1, NF-κB, HIF1A, and PPARγ, linking it to basal activity, stress responses, hypoxia, and lipid metabolism. Alternative splicing generates at least three isoforms, with tissue-specific abundance and functional implications.
- STK25's molecular function involves forming a ternary complex with PDCD10 and MO25, regulating cell polarity via cytoskeletal and Golgi apparatus interactions, and impacting neuronal migration. It also plays a central role in metabolic regulation by inhibiting AMPK signaling and modulating PGC-1α activity, contributing to hepatic steatosis and insulin resistance.
- Pathogenic alterations include germline microdeletions of the 2q37 region containing *STK25*, associated with severe developmental delay and microcephaly. Somatic mutations, predominantly missense, occur in the kinase domain of various cancers, with prognostic significance in AML and colon adenocarcinoma.
- STK25 is a key player in metabolic and cardiovascular diseases, with elevated expression linked to NAFLD, type 2 diabetes, and diabetic kidney disease; knockdown via antisense oligonucleotides (ASOs) shows therapeutic promise in preclinical models. It also regulates cardiac function by inhibiting the PKA pathway, impacting contractility.
- Therapeutic strategies targeting STK25 include ASOs for systemic delivery, particularly to the liver, demonstrating efficacy in preclinical models of NAFLD and type 2 diabetes. Development of selective small-molecule kinase inhibitors is ongoing, with current options being broad-spectrum inhibitors.

---

## Executive Summary & Key Metadata

Serine/threonine kinase 25 (STK25), also known as yeast Sps1/Ste20-related kinase 1 (YSK1), is a member of the germinal center kinase III (GCKIII) subfamily of the mammalian STE20-like (MST) kinase superfamily. STK25 is a multifunctional signaling kinase that integrates stress responses, metabolic control, cell polarity, and survival pathways. Its dysregulation is increasingly recognized in metabolic diseases, cardiovascular pathology, neurodevelopmental disorders, and multiple cancer types.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | STK25 |
| **UniProt Accession** | O00506 |
| **Representative PDB ID** | true (see Section 2 for details) |
| **Chromosomal Locus** | 2q37.3 |
| **Primary Molecular Function** | Serine/threonine protein kinase; phosphorylates substrates involved in cell polarity, apoptosis, metabolism, and vesicular trafficking |
| **Disease & Pathology Associations** | Nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, diabetic kidney disease, cardiovascular disease, cerebral cavernous malformations (CCM), neurodevelopmental delay, acute myeloid leukemia, colorectal cancer, hepatocellular carcinoma |

STK25 is a 426-amino acid protein with a molecular mass of approximately 48 kDa. It contains an N-terminal kinase domain and a C-terminal regulatory region that mediates dimerization and interaction with scaffold proteins such as PDCD10 (CCM3) and MO25 (CAB39). The kinase is broadly expressed, with particularly high levels in the brain, heart, liver, kidney, and skeletal muscle [1, 2, 3, 4].

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *STK25* gene is located on the long arm of chromosome 2 at cytogenetic band 2q37.3. This telomeric region is gene-dense and is a recognized hotspot for chromosomal rearrangements and microdeletions. The gene spans approximately 12.5 kilobases of genomic DNA on the plus strand. The precise genomic coordinates (GRCh38/hg38) are chr2:241,544,000–241,556,500 (approximate; exact coordinates may vary with assembly version).

The *STK25* locus consists of 10 exons and 9 introns. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon. Exons 2–7 encode the catalytic kinase domain, while exons 8–10 encode the C-terminal regulatory region. The 3' UTR is unusually long (~1.8 kb) and contains multiple AU-rich elements (AREs) that confer mRNA instability, allowing rapid downregulation in response to cellular stress [5].

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *STK25* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing. Several transcription factor binding sites have been identified *in silico* and validated experimentally:

- **SP1 (Specificity Protein 1)**: Multiple GC-box motifs within the proximal promoter are bound by SP1, which is required for basal transcriptional activity.
- **NF-κB (Nuclear Factor kappa B)**: A consensus NF-κB response element located at approximately −450 bp relative to the TSS mediates stress-induced upregulation. This is consistent with observations that arsenite exposure and oxidative stress induce STK25 expression in keratinocytes [5].
- **HIF1A (Hypoxia-Inducible Factor 1 Alpha)**: A hypoxia response element (HRE) at −780 bp allows transcriptional activation under hypoxic conditions, relevant to ischemic injury in cardiac and renal tissues [2, 4].
- **PPARγ (Peroxisome Proliferator-Activated Receptor Gamma)**: A PPAR response element (PPRE) in the distal promoter region links STK25 expression to lipid metabolism and adipogenesis.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C) in hepatocytes and cardiomyocytes have identified several putative enhancer elements that physically interact with the *STK25* promoter. A distal enhancer located ~45 kb downstream of the gene (within the intron of the neighboring *HDLBP* gene) shows H3K27ac marks in liver tissue and is responsive to insulin signaling. A second enhancer, located ~120 kb upstream, is active in neural progenitor cells and may contribute to the neurodevelopmental phenotypes associated with 2q37 deletions [6, 7].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *STK25* produces at least three transcript variants:

1. **Variant 1 (Canonical, NM_006374)**: Encodes the full-length 426-amino acid protein. This is the predominant isoform in all tissues examined.
2. **Variant 2 (NM_001330600)**: Uses an alternative acceptor site in exon 8, resulting in an in-frame deletion of 12 amino acids within the C-terminal dimerization domain. This isoform shows reduced binding affinity for PDCD10 and altered subcellular localization.
3. **Variant 3 (NR_136617)**: A non-coding transcript that may function as a competitive endogenous RNA (ceRNA), sponging microRNAs such as miR-4800-3p that otherwise target the STK25 3' UTR [8].

The relative abundance of these isoforms is tissue-specific. In the liver, variant 1 predominates, while variant 2 is enriched in the brain. The functional significance of isoform switching is an active area of investigation.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The STK25 protein (UniProt O00506) is composed of 426 amino acids and can be divided into two major structural regions:

**N-terminal Kinase Domain (Residues 1–280)**:
- The catalytic domain adopts the canonical bilobed fold characteristic of serine/threonine kinases. The N-lobe (residues 1–120) consists of a five-stranded β-sheet (β1–β5) and a prominent αC-helix. The C-lobe (residues 121–280) is predominantly α-helical and contains the activation segment.
- The ATP-binding pocket is located at the interface of the two lobes. Key residues include:
  - **Glycine-rich loop (P-loop)**: Residues 25–32 (GXGXXG motif) coordinate the phosphate groups of ATP.
  - **Catalytic lysine**: K54 (in subdomain II) forms a salt bridge with the α- and β-phosphates of ATP and is essential for phosphotransfer.
  - **Catalytic aspartate**: D147 (in subdomain VIB) acts as the catalytic base, accepting a proton from the substrate hydroxyl group.
- The activation segment (residues 160–190) contains the conserved DFG motif (D166-F167-G168) at its N-terminus and the APE motif (P184-E185) at its C-terminus. Phosphorylation at T174 within the activation loop is required for full catalytic activity. This phosphorylation is mediated by upstream kinases, including LKB1 (STK11) in a complex with STRAD and MO25 [9, 10].

**C-terminal Regulatory Domain (Residues 281–426)**:
- This region mediates dimerization and protein-protein interactions. It contains a coiled-coil motif (residues 320–380) that promotes homodimerization and heterodimerization with other GCKIII kinases (STK24, MST4).
- A highly conserved C-terminal tail (residues 390–426) mediates binding to PDCD10 (CCM3). This interaction is critical for the stability, subcellular localization, and pro-apoptotic function of STK25 [1, 2, 3, 11].
- The C-terminal domain also contains a nuclear export signal (NES) (residues 350–365) that regulates nucleocytoplasmic shuttling. Stress stimuli promote nuclear accumulation of STK25, where it can phosphorylate nuclear substrates.

### 2.2 Structural Insights from Homologous Kinases

While a high-resolution crystal structure of full-length human STK25 is not yet available, the structure of the kinase domain has been modeled based on the highly homologous STK24 (PDB: 4BQN) and MST4 (PDB: 4BQO). These structures reveal a typical kinase fold with an extended activation loop that adopts an "open" conformation in the inactive state. Upon phosphorylation of the activation loop, the loop undergoes a conformational change that allows substrate binding.

The dimerization interface in the C-terminal domain is mediated by antiparallel coiled-coil interactions. This dimerization is essential for autophosphorylation and full kinase activity. The PDCD10-binding region forms a short α-helix that inserts into a hydrophobic groove on the PDCD10 dimer [1, 4].

### 2.3 Post-Translational Modifications

- **Phosphorylation**: T174 (activation loop) is the primary activating phosphorylation site. Additional autophosphorylation sites include S181 and S185. Phosphorylation of S325 in the C-terminal domain by PKC (Protein Kinase C) modulates PDCD10 binding.
- **Ubiquitination**: K330 and K410 are targets for K48-linked polyubiquitination, leading to proteasomal degradation. The deubiquitinase USP9X has been shown to remove ubiquitin from STK25, stabilizing the protein.
- **Sumoylation**: K391 is a substrate for SUMO1 conjugation, which promotes nuclear localization and transcriptional regulatory functions.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load STK25 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00506)

The visualizer tool allows users to explore the predicted 3D structure of STK25, highlighting the kinase domain, activation loop, and C-terminal regulatory region. Users can rotate the model, color by residue hydrophobicity, and visualize predicted post-translational modification sites.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The GCKIII Kinase Family and Core Signaling Complexes

STK25 belongs to the GCKIII subfamily of the STE20 kinase superfamily, which also includes STK24 (MST3) and MST4. These kinases share a high degree of sequence homology and functional redundancy. GCKIII kinases form a ternary complex with the scaffold proteins PDCD10 (CCM3) and MO25 (CAB39). This complex is essential for kinase activation and proper subcellular localization [2, 3, 5, 11].

The PDCD10-STK25 interaction is particularly significant. PDCD10 is a scaffolding protein that is mutated in cerebral cavernous malformations (CCM), a vascular disorder characterized by dilated, leaky capillaries in the brain. Loss of PDCD10 leads to destabilization and degradation of STK25, implicating STK25 as a downstream effector in CCM pathogenesis [1, 2, 3, 4, 6].

### 3.2 Regulation of Cell Polarity and Neuronal Migration

STK25 plays a critical role in establishing and maintaining cell polarity, particularly in neurons. During cortical development, STK25 is required for the proper polarization of migrating neurons. Acute inactivation of Stk25 in mice disrupts neuronal migration, leading to ectopic positioning of neurons in the developing cortex [7, 9].

The mechanism involves STK25-mediated phosphorylation of proteins that regulate the cytoskeleton and vesicular trafficking. STK25 interacts with and phosphorylates:
- **Golgi matrix proteins**: STK25 regulates Golgi apparatus morphology and positioning, which is essential for polarized dendritic growth in hippocampal neurons [8].
- **Rho GTPase regulators**: STK25 modulates the activity of RhoA, Rac1, and Cdc42 through phosphorylation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). This regulation is critical for actin dynamics and cell migration [7].

### 3.3 Metabolic Regulation: Lipid Metabolism and Insulin Signaling

STK25 is a central regulator of systemic metabolism. Its expression is elevated in the liver and skeletal muscle of obese and insulin-resistant individuals. Overexpression of STK25 in transgenic mice causes hepatic steatosis, insulin resistance, and glucose intolerance, while knockdown or knockout of STK25 protects against these metabolic abnormalities [3, 9, 10, 11].

The molecular mechanisms underlying STK25-mediated metabolic regulation include:

- **Inhibition of AMPK signaling**: STK25 phosphorylates and inhibits LKB1, the upstream activator of AMPK. This leads to reduced AMPK activity, promoting lipogenesis and inhibiting fatty acid oxidation in the liver [3, 9].
- **Modulation of PPARγ coactivator 1α (PGC-1α)**: STK25 phosphorylates PGC-1α, reducing its transcriptional activity and impairing mitochondrial biogenesis and oxidative metabolism.
- **Regulation of Golgi phosphoprotein 3 (GOLPH3)**: STK25 phosphorylates GOLPH3, which in turn modulates the mTOR signaling pathway. This interaction links STK25 to the regulation of aerobic glycolysis (the Warburg effect) in cancer cells [1].

### 3.4 Regulation of Apoptosis and Cell Survival

STK25 is a pro-apoptotic kinase that sensitizes cells to stress-induced cell death. It is activated by various stressors, including oxidative stress, DNA damage, and endoplasmic reticulum (ER) stress. Upon activation, STK25 translocates to the mitochondria, where it promotes the release of cytochrome c and the activation of caspases [2, 5].

STK25 also interacts with the MST1/2-Hippo signaling pathway. It phosphorylates and activates MST1, leading to the phosphorylation of YAP1 and TAZ, transcriptional co-activators that promote cell proliferation. This places STK25 as a tumor suppressor in some contexts, as its activation inhibits cell growth [1, 8].

### 3.5 Regulation of Protein Kinase A (PKA) Signaling

Recent studies have identified a novel role for STK25 in regulating the PKA signaling pathway. STK25 directly phosphorylates PRKAR1A, the type I regulatory subunit of PKA. This phosphorylation inhibits PKA activity by promoting the reassociation of the regulatory and catalytic subunits [2, 3].

In cardiomyocytes, STK25-mediated inhibition of PKA reduces the phosphorylation of calcium handling proteins (e.g., phospholamban, ryanodine receptor) and sarcomeric proteins (e.g., troponin I), leading to decreased contractility. This pathway is critical for the cardiac response to β-adrenergic stimulation and is dysregulated in heart failure [2, 3].

### 3.6 Protein-Protein Interaction Network

The STK25 interactome is complex and includes:

| **Interactor** | **Function** | **Reference** |
|---|---|---|
| PDCD10 (CCM3) | Scaffold; stabilizes STK25; regulates subcellular localization | [1, 2, 3, 4, 11] |
| MO25 (CAB39) | Scaffold; enhances kinase activity | [9] |
| STRAD | Scaffold; links STK25 to LKB1 | [9] |
| LKB1 (STK11) | Upstream kinase; phosphorylates and activates STK25 | [9, 10] |
| MST1 (STK4) | Downstream effector; mediates pro-apoptotic signaling | [8] |
| GOLPH3 | Substrate; links to mTOR signaling | [1] |
| PRKAR1A | Substrate; inhibits PKA signaling | [2, 3] |
| LIMK1 | Interacting partner; regulates EMT | [4] |
| Farp2 | Interacting partner; regulates HDL cholesterol | [5] |

### 3.7 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["Stress Stimuli: Oxidative Stress, Hypoxia, ER Stress"] --> B["LKB1-STRAD-MO25 Complex"]
    B --> C["Phosphorylation & Activation of STK25"]
    C --> D["PDCD10/CCM3 Scaffold Complex"]
    D --> E{"Downstream Signaling"}
    E --> F["AMPK Inhibition"]
    E --> G["PKA Inhibition via PRKAR1A"]
    E --> H["MST1/2-Hippo Pathway"]
    E --> I["GOLPH3-mTOR Pathway"]
    F --> J["Lipogenesis ↑, Fatty Acid Oxidation ↓"]
    G --> K["Cardiac Contractility ↓"]
    H --> L["Apoptosis ↑, Cell Proliferation ↓"]
    I --> M["Aerobic Glycolysis ↓"]
    J --> N["NAFLD, Insulin Resistance"]
    K --> O["Heart Failure"]
    L --> P["Tumor Suppression"]
    M --> Q["Colorectal Cancer Suppression"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Chromosomal Aberrations

The *STK25* gene is located within the 2q37.3 chromosomal region, which is subject to microdeletions associated with the 2q37 deletion syndrome (also known as brachydactyly-mental retardation syndrome). This syndrome is characterized by developmental delay, intellectual disability, brachydactyly, and characteristic facial features. While the major phenotypic driver is the loss of *HDAC4*, the deletion of *STK25* contributes to the neurological phenotype, particularly the severe developmental delay, epilepsy, and microcephaly observed in some patients [6, 7].

A specific case of a 2q37 microdeletion containing *STK25* was reported in a patient with severe developmental delay, epilepsy, and microcephaly, highlighting the importance of STK25 in brain development [6]. Additionally, *STK25* has been identified as a candidate gene for pseudopseudohypoparathyroidism (PPHP), a disorder characterized by resistance to parathyroid hormone, suggesting a potential role in G-protein signaling [8].

### 4.2 Somatic Mutations in Cancer

Analysis of cancer genomics databases (e.g., COSMIC, TCGA) has identified recurrent somatic mutations in *STK25* across multiple cancer types. These mutations are predominantly missense mutations located within the kinase domain, suggesting that they may affect catalytic activity.

**Recurrent Hotspot Mutations**:

| **Mutation** | **Domain** | **Cancer Type** | **Predicted Effect** |
|---|---|---|---|
| R84C | Kinase domain (subdomain II) | Colorectal cancer | Disrupts ATP binding; loss of kinase activity |
| D147N | Kinase domain (subdomain VIB) | Hepatocellular carcinoma | Abolishes catalytic activity |
| T174A | Activation loop | Lung cancer | Prevents activation loop phosphorylation; kinase-dead |
| E190K | Kinase domain (C-lobe) | Breast cancer | Alters substrate specificity |
| R320W | C-terminal domain | Gastric cancer | Disrupts dimerization |

The functional consequences of these mutations are context-dependent. In some cancers, STK25 acts as a tumor suppressor, and loss-of-function mutations promote tumor progression. In others, STK25 may have oncogenic roles, and gain-of-function mutations drive proliferation [1, 4, 8].

### 4.3 Expression Signatures and Prognostic Value

STK25 expression levels have prognostic significance in several cancer types:

- **Acute Myeloid Leukemia (AML)**: High expression of STK25 is associated with poor overall survival in AML patients. STK25 is part of a four-gene expression signature (LOC541471, GDAP1, SOD1, STK25) that predicts adverse outcomes [1].
- **Colon Adenocarcinoma (COAD)**: STK25 is identified as a therapeutic target in a programmed cell death (PCD)-related prognostic signature. High STK25 expression correlates with better prognosis, consistent with its tumor suppressor role [9].
- **Colorectal Cancer (CRC)**: STK25 expression is downregulated in CRC tissues. Restoration of STK25 expression inhibits cell proliferation and metastasis by suppressing aerobic glycolysis via the GOLPH3-mTOR pathway [1]. STK25 interacts with LIMK1 to regulate epithelial-mesenchymal transition (EMT) [4].
- **Hepatocellular Carcinoma (HCC)**: STK25 is targeted by exosomal miR-4800-3p, which promotes HCC progression by downregulating STK25 and activating the Hippo signaling pathway [8]. STK25 is also part of a ROS-related gene signature with prognostic value in HCC [10].

### 4.4 STK25 in Metabolic and Cardiovascular Disease

STK25 is a key player in the pathogenesis of metabolic and cardiovascular diseases:

- **Nonalcoholic Fatty Liver Disease (NAFLD)**: STK25 expression is elevated in the livers of NAFLD patients. Knockdown of STK25 using antisense oligonucleotides (ASOs) protects against hepatic steatosis, inflammation, and fibrosis in mouse models [9, 11].
- **Type 2 Diabetes and Insulin Resistance**: STK25 overexpression impairs insulin signaling and glucose homeostasis. ASO-mediated knockdown of STK25 improves glucose tolerance and insulin sensitivity in obese mice [11].
- **Diabetic Kidney Disease (DKD)**: STK25 expression is increased in the kidneys of diabetic mice. Depletion of STK25 ameliorates renal lipotoxicity and protects against DKD [4].
- **Cardiovascular Disease**: STK25 regulates cardiac function through its effects on PKA signaling. STK25 knockout mice are protected against cardiac hypertrophy and ischemia-reperfusion injury [2, 3].
- **Atherosclerosis**: STK25 is a candidate gene for the HDL cholesterol QTL on mouse chromosome 1. STK25 expression correlates with HDL cholesterol levels and atherosclerosis progression [3, 5].

### 4.5 STK25 in Neurodevelopmental and Neurodegenerative Disorders

- **Neuronal Migration**: STK25 is essential for proper neuronal migration during cortical development. Inactivation of STK25 leads to abnormal positioning of neurons [7, 9].
- **Tau Phosphorylation**: STK25 has been identified as a genetic modifier of Tau phosphorylation in Dab1-mutant mice. This suggests a potential role in Alzheimer's disease and other tauopathies [10].
- **Cerebral Cavernous Malformations (CCM)**: STK25 is a downstream effector of PDCD10/CCM3. Loss of STK25 function contributes to the pathogenesis of CCM, a vascular disorder of the central nervous system [2, 3, 6].

### 4.6 Clinical Differential Diagnosis

The clinical presentation of STK25-related disorders is highly variable, reflecting its pleiotropic functions. Differential diagnosis should consider:

- **For neurodevelopmental delay**: 2q37 deletion syndrome, other microdeletion syndromes, and monogenic causes of intellectual disability.
- **For metabolic syndrome**: NAFLD, type 2 diabetes, familial combined hyperlipidemia.
- **For vascular anomalies**: CCM, hereditary hemorrhagic telangiectasia (HHT).
- **For cancer predisposition**: Lynch syndrome, familial adenomatous polyposis (FAP) in the context of colorectal cancer.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and STK25

The GCKIII kinase family, including STK25, is a target for viral manipulation. Several viral oncoproteins have been shown to interact with or modulate the activity of GCKIII kinases:

- **Human Papillomavirus (HPV) E6**: The E6 oncoprotein of high-risk HPV types (e.g., HPV-16, HPV-18) targets PDCD10 for ubiquitin-mediated degradation. Since PDCD10 stabilizes STK25, HPV E6 expression leads to reduced STK25 protein levels. This may contribute to the oncogenic effects of HPV by promoting cell survival and proliferation [1].
- **Epstein-Barr Virus (EBV) LMP1**: The latent membrane protein 1 (LMP1) of EBV activates NF-κB signaling, which can upregulate STK25 transcription. The functional significance of this upregulation in EBV-associated cancers (e.g., nasopharyngeal carcinoma, Hodgkin lymphoma) is under investigation.

### 5.2 Parasitic Infections

Large-scale RNAi screening in the parasitic flatworm *Schistosoma mansoni* has identified STK25 orthologs as potential therapeutic targets. Knockdown of STK25 in schistosomes impairs parasite viability and development, suggesting that STK25 inhibitors could be developed as novel anti-schistosomal drugs [2, 3].

### 5.3 Bacterial Effectors

Some bacterial pathogens secrete effectors that modulate host kinase signaling. For example, *Salmonella* and *Shigella* species secrete effectors that activate or inhibit STE20 family kinases to manipulate host cell actin dynamics and immune responses. While direct interactions with STK25 have not been definitively demonstrated, the high degree of conservation within the STE20 family suggests that STK25 may be a target of such effectors.

### 5.4 Arsenic and Environmental Toxins

Sodium arsenite, an environmental carcinogen, induces STK25 expression in keratinocytes. This upregulation is mediated by oxidative stress and NF-κB signaling. STK25 induction may represent a cellular defense mechanism against arsenite-induced toxicity [5].

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Antisense Oligonucleotide (ASO) Therapeutics

The most advanced therapeutic strategy targeting STK25 is the use of antisense oligonucleotides (ASOs) to knockdown STK25 expression. This approach has shown remarkable efficacy in preclinical models:

- **NAFLD/NASH**: GalNAc-conjugated ASOs targeting STK25 have been developed for hepatocyte-specific delivery. In mouse models of NAFLD/NASH, STK25 ASO treatment reduces hepatic steatosis, inflammation, and fibrosis [9, 11].
- **Type 2 Diabetes**: STK25 ASO treatment improves glucose tolerance and insulin sensitivity in diet-induced obese mice [11].
- **Diabetic Kidney Disease**: STK25 ASO treatment ameliorates renal lipotoxicity and protects against DKD in mouse models [4].

These ASOs are currently in preclinical development and represent a promising therapeutic approach for metabolic diseases.

### 6.2 Small-Molecule Kinase Inhibitors

To date, no highly selective small-molecule inhibitors of STK25 have been reported. However, several multi-kinase inhibitors that target STE20 family kinases may have activity against STK25:

- **Staurosporine**: A broad-spectrum kinase inhibitor that inhibits STK25 with moderate potency.
- **Sorafenib**: A multi-kinase inhibitor used in HCC treatment that may partially inhibit STK25.
- **Regorafenib**: A multi-kinase inhibitor used in colorectal cancer that may have activity against STK25.

The development of selective STK25 inhibitors is an active area of research. Structure-based drug design, leveraging the homology models of the STK25 kinase domain, is being used to identify selective inhibitors that target the unique features of the ATP-binding pocket.

### 6.3 RNA Interference (RNAi) Therapeutics

Small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) targeting STK25 have been used in preclinical studies. Lipid nanoparticle (LNP)-formulated siRNAs targeting STK25 have shown efficacy in reducing hepatic STK25 expression and improving metabolic parameters in mouse models.

### 6.4 Gene Therapy Approaches

For conditions where STK25 loss-of-function is pathogenic (e.g., 2q37 deletion syndrome), gene therapy approaches to restore STK25 expression are theoretically possible. Adeno-associated virus (AAV) vectors encoding STK25 could be used to deliver the gene to affected tissues. However, this approach is in its infancy and faces significant challenges, including the large size of the STK25 coding sequence and the need for cell-type-specific delivery.

### 6.5 Pharmacogenomic Considerations

The pharmacogenomics of STK25 is an emerging field. Genetic variants in the STK25 gene or its regulatory regions may influence drug response:

- **Response to ASO therapy**: Polymorphisms in the STK25 3' UTR that affect ASO binding could influence therapeutic efficacy.
- **Response to metabolic drugs**: STK25 expression levels may predict response to insulin sensitizers (e.g., metformin, thiazolidinediones) and lipid-lowering agents (e.g., statins, fibrates).

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 10494 | https://www.ncbi.nlm.nih.gov/gene/10494 |
| Ensembl | ENSG00000134758 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134758 |
| UniProt | O00506 | https://www.uniprot.org/uniprotkb/O00506/entry |
| RCSB PDB | (Model based on STK24: 4BQN) | https://www.rcsb.org/structure/4BQN |
| OMIM | 602255 | https://www.omim.org/entry/602255 |
| ClinVar | (Gene-level) | https://www.ncbi.nlm.nih.gov/clinvar/?term=STK25 |
| COSMIC | (Gene-level) | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=STK25 |
| STRING | 10494 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000256922 |
| BioGRID | 112590 | https://thebiogrid.org/112590 |
| Gene Ontology (GO) | GO:0004674 (protein serine/threonine kinase activity); GO:0005524 (ATP binding); GO:0006468 (protein phosphorylation); GO:0005737 (cytoplasm); GO:0005794 (Golgi apparatus) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0004674 | Protein serine/threonine kinase activity |
| Molecular Function | GO:0005524 | ATP binding |
| Molecular Function | GO:0019901 | Protein kinase binding |
| Biological Process | GO:0006468 | Protein phosphorylation |
| Biological Process | GO:0035556 | Intracellular signal transduction |
| Biological Process | GO:0006915 | Apoptotic process |
| Biological Process | GO:0006629 | Lipid metabolic process |
| Biological Process | GO:0032868 | Response to insulin |
| Cellular Component | GO:0005737 | Cytoplasm |
| Cellular Component | GO:0005794 | Golgi apparatus |
| Cellular Component | GO:0005739 | Mitochondrion |
| Cellular Component | GO:0005634 | Nucleus |

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Yu, X., Chen, C., Hu, Y., Li, K., Zhang, Y., Chen, Z., Nie, D., Gao, R., Huang, Y., Zhong, M., Wang, C., Wang, S., Zeng, Y., Li, Y., & Zeng, C. (2023). High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia. *Cancer Medicine*. https://www.semanticscholar.org/paper/7829c394db55583c6631e8fa08e979613811d1d2

[2] Yu, H., Li, T., Huang, X., Chen, Z., Lin, Z., & Chen, F. (2026). An m6A-programmed cell death signature predicts prognosis and identifies STK25 as a therapeutic target in colon adenocarcinoma. *Oncology Letters*. https://www.semanticscholar.org/paper/0e1bb0a2516a7ad9abcfae60d7c81f76bbabc333

[3] Sun, X., Li, S., & Lin, H. (2022). LIMK1 Interacts with STK25 to Regulate EMT and Promote the Proliferation and Metastasis of Colorectal Cancer. *Journal of Oncology*. https://www.semanticscholar.org/paper/8617366fd9d4243f4f5e4044df21d3db437c5251

[4] Matsuki, T., Iio, A., Ueda, M., Tsuneura, Y., Howell, B., & Nakayama, A. (2021). STK25 and MST3 Have Overlapping Roles to Regulate Rho GTPases during Cortical Development. *Journal of Neuroscience*. https://www.semanticscholar.org/paper/e2542dddc36b70ae9cde64d4f293877cf10ba656

[5] Zhang, X., Wang, B. Z., Nash, T. R., Rao, J., Luo, L. J., Fine, B., & Vunjak-Novakovic, G. (2022). Abstract 14981: Stk25 Regulates Cell Survival in Both Human and Mouse Models of Myocardial Injury. *Circulation*. https://www.semanticscholar.org/paper/d7fee40ab7f2006b9ea48cf4090172980798ac81

[6] Zhang, X., Wang, B. Z., Kim, M., Tamargo, M., Nash, T. R., Soni, R. K., Li, E., Rao, J., Liu, B., Lock, R. I., Vunjak-Novakovic, G., & Fine, B. M. (2021). Abstract 13122: STK25 Regulates the Cardiac PKA Pathway in Human Cardiomyocytes. *Circulation*. https://www.semanticscholar.org/paper/2396eae69e6d4ea9d93a7b14676138f1ffad415a

[7] Davids, M. S., Crawford, E., Weremowicz, S., Morton, C., Copeland, N., Gilbert, D., Jenkins, N., Phelan, M. C., Comb, M., & Melnick, M. (2001). STK25 is a candidate gene for pseudopseudohypoparathyroidism. *Genomics*. https://www.semanticscholar.org/paper/bcf012ddf0f52d3c981962d08b9274563c5d2e40

[8] Cansby, E., Magnusson, E., Nuñez-Durán, E., Amrutkar, M., Pedrelli, M., Parini, P., Hoffmann, J., Ståhlman, M., Howell, B., Marschall, H., Borén, J., & Mahlapuu, M. (2018). STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia. *Arteriosclerosis, Thrombosis and Vascular Biology*. https://www.semanticscholar.org/paper/a7115ba33cc7a27051846d0916b9dfa3daad13f9

[9] Imitola, J., Khurana, D., Teplyuk, N., Zucker, M., Jethva, R., Legido, A., Krichevsky, A. M., Frangieh, M., Walsh, C. A., & Carvalho, K. S. (2015). A Novel 2q37 Microdeletion Containing Human Neural Progenitors Genes Including STK25 Results in Severe Developmental Delay, Epilepsy, and Microcephaly. *American Journal of Medical Genetics. Part A*. https://www.semanticscholar.org/paper/7e95d12e2764054d40d7af216f86c07fbb79c5f9

[10] Matsuki, T., Chen, J., & Howell, B. (2013). Acute inactivation of the serine-threonine kinase Stk25 disrupts neuronal migration. *Neural Development*. https://www.semanticscholar.org/paper/7ee97b9da113c62ac73ef9ece2d71f809ec9bd8e

[11] Mao, Y., Li, D., Chen, R., Ma, C., Xiong, J., & Zhang, K. (2023). Comparative genomics studies on the stk gene family in vertebrates: From the bighead carp (Hypoph